Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>CMBI Recommends INNOVENT BIO/ 3SBIO, Anticipates Fundamentals of CN Healthcare Industry to Accelerate Improvement
Recommend 8 Positive 14 Negative 7 |
||||
|
||||
|
The MSCI China Healthcare Index has increased by 0.6% YTD, outpacing the MSCI China Index by 3.5%, according to a report from CMBI. The pharmaceutical industry has recently experienced a marked pullback, especially in the innovative drug segment. With the policy catalyst of the Chinese government's work report listing biopharmaceuticals as an emerging pillar industry, the sector's risk appetite has moderately improved of late. Meanwhile, breakthroughs in AI pharmaceutical technology and the explosion of Chinese innovative drugs entering overseas business development have formed a dual resonance, upon which CMBI expects the industry's fundamentals to accelerate improvement. CMBI recommends buying INNOVENT BIO (01801.HK), 3SBIO (01530.HK), JACOBIO-B (01167.HK), GUSHENGTANG (02273.HK), and WUXI XDC (02268.HK), with target prices of HKD110.62, HKD37.43, HKD10.34, HKD44.95, and HKD88, respectively. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
